Table 1 Patient characteristics and SBRT treatment details
Variable | N (%) |
|---|---|
Median Age, years (range) | 69 (18–93) |
Gender | |
Male | 223 (49.9%) |
Female | 221 (49.4%) |
Not reported | 3 (0.01%) |
Median Karnofsky Performance Score (range) | 90 (30–100) |
Ethnicity | |
African-American | 24 (5.4%) |
Asian | 2 (0.5%) |
Caucasian | 325 (72.7%) |
Hispanic | 17 (3.8%) |
Other | 1 (0.2%) |
Unknown | 14 (3.1%) |
Not reported | 64 (14.3%) |
Prior Chemotherapy | 220 (49.2%) |
Median Lesion Volume, cc (range) | 10.58 (0.1–654.5) |
Primary Tumor Location | |
Breast | 41 (9.2%) |
Colorectal | 115 (25.7%) |
Head & Neck | 51 (11.4%) |
Lung | 74 (16.6%) |
Kidney | 36 (8.1%) |
Skin | 29 (6.5%) |
Other | 99 (22.1%) |
Not reported | 2 (0.4%) |
Median SBRT Dose, Gy (range) | 50 (8–60) |
Median Max Dose, Gy (range) | 68.2 (10.3–78) |
Median Number of Fractions (range) | 3 (1–8) |
Median Monte Carlo Dose, Gy (range) | 45.6 (8–60) |
Median Monte Carlo Dose (Gy) per Fraction | 13 (2–40) |
Median Monte Carlo BED, (range) | 100 (9–204) |